Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis

Haematologica

Volumn 92, Issue 12, 2007, Pages 1585-1589

  Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; JANUS KINASE 2;

COMPARATIVE STUDY; EDITORIAL; ERYTHROCYTOSIS; GENE MUTATION; GENETIC POLYMORPHISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SOMATIC MUTATION;

ALLELES; AMINO ACID SUBSTITUTION; BONE MARROW; COHORT STUDIES; ERYTHROID PROGENITOR CELLS; ERYTHROPOIETIN; EXONS; GREAT BRITAIN; HUMANS; IRELAND; JANUS KINASE 2; POLYCYTHEMIA; POLYCYTHEMIA VERA; PREVALENCE;

EID: 37049036160     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11506     Document Type: Editorial

References (24)

1. Hillman RS, Finch CA. Red Cell Manual. 5 ed. Philadelphia: F.A. Davis; 1985.
2. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.
3. Cockman ME, Pugh CW. Oxygen sensing. Haematologica 2005;90:8-12.
4. Semenza GL. Life with oxygen. Science 2007;318:62-4.
5. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007;2007:cm8.
6. D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 1990;86:681-7.
7. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991; 77:2583-90.
8. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
9. Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/ erythrocytoses. Haematologica 2005;90:109-16.
10. Bento MC, Chang KT, Guan Y, Liu E, Caldas G, Gatti RA, et al. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. Haematologica 2005;90:128-9.
11. Cario H, Schwarz K, Jorch N, Kyank U, Petrides PE, Schneider DT, et al. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 2005;90:19-24.
12. Randi ML, Murgia A, Putti MC, Martella M, Casarin A, Opocher G, et al. Low frequency of VHL gene mutations in young individuals with polycythemia and high serum erythropoietin. Haematologica 2005;90:689-91.
13. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-82.
14. Cazzola M, Passamonti F. Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica 2006;91:159.
15. Cazzola M, Skoda R. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica 2005;90:871-4.
16. Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007, in press.
17. Percy MJ, Jones FG, Green AR, Reilly JT, McMullin MF. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica 2006;91:413-4.
18. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459-68.
19. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-3.
20. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 2007; 35:1641-6.
21. Butcher CM, Hahn U, To LB, Gecz J, Wilkins EJ, Scott HS, et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2007; [Epub ahead of print].
22. Percy MJ, Scott LM, Erber WN, Harrison CN, Jones FCG, Green AR, et al. JAK2 exon 12 mutations occurr frequently in idiopathic erythrocytosis patients widi low serum erythropoietin levels. Haematologica 2007;92:1607-14.
23. Martínez-Aviles L, Besses C, Alvarez-Larran A, Cervantes F, Hernandez-Boluda JC, Bellosillo B. JAK2 exon 12 mutations in patients with polycythemia vera or idiopathic erythrocytosis. Haematologica 2007;92:1717-18.
24. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2007 Nov 6; [Epub ahead of print].